Pafolacianine

From WikiMD's Wellness Encyclopedia

What is Pafolacianine?[edit | edit source]


Pafolacianine skeletal
Pafolacianine structural components



What are the uses of this medicine?[edit | edit source]


How does this medicine work?[edit | edit source]

  • Cytalux is a fluorescent drug that targets folate receptor (FR) which may be overexpressed in ovarian cancer.
  • Pafolacianine binds to FR-expressing cancer cells internalizes via receptor mediated endocytosis, and concentrates in FR-positive cancer tissues.
  • Pafolacianine absorbs light in the near-infrared (NIR) region within a range of 760 nm to 785 nm with peak absorption of 776 nm and emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.


Who Should Not Use this medicine ?[edit | edit source]

  • This medicine have no usage limitations.


What drug interactions can this medicine cause?[edit | edit source]

  • Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors overexpressed on ovarian cancer cells and could reduce the detection of malignant lesions with Cytalux.
  • Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of Cytalux.


Is this medicine FDA approved?[edit | edit source]

  • It was approved for medical use in the United States in November 2021.


How should this medicine be used?[edit | edit source]

  • Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy prior to administration of Cytalux.
  • Discontinue folate, folic acid, or folate containing supplements 48 hours before administration of Cytalux.
  • Consider administering antihistamines and/or anti-nausea medication for prophylaxis against infusion related reactions.

Recommended dosage and administration:

  • The recommended dose of Cytalux is a single intravenous infusion of 0.025 mg/kg diluted in 250 mL of 5% Dextrose Injection, administered over 60 minutes using a dedicated infusion line, 1 hour to 9 hours prior to surgery.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Injection: 3.2 mg/1.6 mL (2 mg/mL) of pafolacianine in a single-dose vial.

This medicine is available in fallowing brand namesː

  • Cytalux


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:


What special precautions should I follow?[edit | edit source]

  • Adverse reactions consisting of nausea, vomiting, abdominal pain, flushing, dyspepsia, chest discomfort, and pruritus were reported in patients receiving Cytalux. Interrupt the infusion and treat as necessary with antihistamines and/or nausea medications.
  • Errors may occur with the use of Cytalux during intraoperative fluorescence imaging to detect ovarian cancer, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor. Fluorescence may be seen in non-cancerous tissues.
  • Cytalux may cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus.
  • Use of the incorrect diluent to prepare the Cytalux infusion solution can cause the aggregation of pafolacianine; aggregation may induce infusion reactions, such as nausea, vomiting, abdominal pain or rash. Use only 5% Dextrose Injection for dilution. Do not use other diluents.


What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.


Can this medicine be used in pregnancy?[edit | edit source]

  • Based on its mechanism of action, pafolacianine may cause fetal harm when administered to a pregnant woman.
  • There are no available human data to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.


Can this medicine be used in children?[edit | edit source]

  • Safety and effectiveness of Cytalux in pediatric patients have not been established.


What are the active and inactive ingredients in this medicine?[edit | edit source]

Active ingredient:

  • PAFOLACIANINE SODIUM

Inactive ingredients:

  • WATER
  • SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
  • SODIUM CHLORIDE
  • HYDROCHLORIC ACID
  • POTASSIUM PHOSPHATE, MONOBASIC
  • SODIUM HYDROXIDE


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured for:

  • On Target Laboratories
  • West Lafayette, IN


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store frozen between -25° to -15°C (-13° to 5°F).
  • Store in original carton to protect from light.


Pafolacianine Resources


Contributors: Deepika vegiraju